NR^aR^a, $-N(R^a)C(=NR^a)NR^aR^a$, $-N(R^a)S(=O)_2R^a$, $-N(R^a)S(=O)_2NR^aR^a$, $-NR^aC_{2-6}alkNR^aR^a$ and $-NR^aC_{2-6}alkOR^a$, wherein the ring is additionally substituted by 0 or 1 directly bonded, SO_2 linked, C(=O) linked or CH_2 linked saturated, partially-saturated or unsaturated 3-, 4-, 5-, 6- or 7-membered monocyclic ring containing 0, 1, 2, 3 or 4 heteroatoms selected from N, O and S, but containing no more than one O or S atom, and substituted by 0, 1, 2 or 3 groups selected from halo, oxo, $C_{1-6}alk$, $C_{1-4}haloalk$, cyano, nitro, $-C(=O)R^a$, $-C(=O)OR^a$, $-C(=O)NR^aR^a$, $-C(=NR^a)NR^aR^a$, $-OR^a$, $-OC(=O)R^a$, $-SR^a$, $-S(=O)R^a$, $-S(=O)_2R^a$, $-S(=O)_2NR^aR^a$, $-NR^aR^a$, and $-N(R^a)C(=O)R^a$;

R^2 is –F or $–CF_3$;

R^3 is $-OCF_3$ or $-CF_3$;

R^4 is ~~independently, at each instance,~~ H, $C_{1-6}alk$, $-C_{1-3}haloalk$, $-OC_{1-6}alk$, $-OC_{1-3}haloalk$, $-N(C_{1-6}alk)C_{1-6}alk$, $-NHC_{1-6}alk$, $-NC(=O)C_{1-6}alk$, $-N(C_{1-6}alk)C_{1-6}alk$, F, Cl, Br, CN, OH or NH_2; ~~or R^3 and R^4 together form a four-atom unsaturated bridge containing 0 or 1 N atoms, wherein the bridge is substituted by 0, 1 or 2 R^5 substituents;~~

R^5 is independently, in each instance, halo, OR^a, CH_3 or CF_3;

R^6 is F, $C_{1-6}alk$, or OR^a;

R^a is independently, at each instance, H or R^b; and

R^b is independently, at each instance, phenyl, benzyl or $C_{1-6}alk$, the phenyl, benzyl and $C_{1-6}alk$ being substituted by 0, 1, 2 or 3 substituents selected from halo, oxo, $C_{1-4}alk$, $C_{1-3}haloalk$, $-OC_{1-4}alk$, -OH, $-NH_2$, $-OC_{1-4}alk$, $-OC_{1-4}haloalk$, $-NHC_{1-4}alk$, and $-N(C_{1-4}alk)C_{1-4}alk$.

2. The compound of claim 1 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, or the mixture thereof, wherein the compound of Formula I has the Formula IA:

the symbol ∿∿∿, when drawn across a bond, indicates the point of attachment to the rest of the molecule.

13. The compound of claim 4 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, or the mixture thereof, wherein R^1 is



and the symbol ∿∿∿, when drawn across a bond, indicates the point of attachment to the rest of the molecule.

14. The compound of claim 1 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, or the mixture thereof, wherein m is 0.

15. The compound of ~~any one of~~ claim 1 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, or the mixture thereof, wherein n is 0.

16. The compound of claim 1 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, or the mixture thereof, wherein R^2 is -F.

17. The compound of claim 1 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, or the mixture thereof, wherein R^2 is $-CF_3$.

18. The compound of claim 1 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, or the mixture thereof, wherein R^3 is $-OCF_3$.

34. The compound or tautomer of any one of claims 1-33 in a neutral form.

35. The pharmaceutically-acceptable salt of the compound or the pharmaceutically acceptable salt of the tautomer of any one of claims 1-33.

36. A pharmaceutical composition comprising the compound according to any one of claims 1-33 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, or the mixture thereof, and a pharmaceutically-acceptable diluent or carrier.

37. Use of the compound according to any one of claims 1-33 or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, or the mixture thereof in the manufacture of a medicament for treating any one of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, depression, anxiety, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders in a subject.

38. The use of claim 37 ~~or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, or the mixture thereof~~ for treating neuropathic pain in a subject.

39. The use of claim 37 ~~or the pharmaceutically-acceptable salt thereof, the tautomer thereof, the pharmaceutically-acceptable salt of the tautomer, or the mixture thereof~~ for treating migraine in a subject.